This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kornblau, S. M. Articles by Deisseroth, A. B. Search for Related Content PubMed PubMed Citation Articles by Kornblau, S. M. Articles by Deisseroth, A. B.

Clinical Implications of Decreased Retinoblastoma Protein Expression in Acute Myelogenous Leukemia¹

Departments of Hematology [S. M. K., A. G., W. Z., L. C., M. B., E. E., M. A., A. B. D.] and Biomathematics [T. L. S.] and the Division of Laboratory Medicine [J. T., M. A. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and the Baylor College of Medicine [H-J. X., S-X. H., W. F. B.], Center for Biotechnology, The Woodland, Texas 77381

The retinoblastoma (RB) protein levels in blast-enriched mononuclear fractions from the peripheral blood of 33 newly diagnosed patients with acute myelogenous leukemia were studied. Ten patients who had previously been treated were also analyzed, nine of whom had achieved prior complete remission. Low RB protein expression was found in 13 of 43 (30%) of the acute myelogenous leukemia patients as determined by Western blotting and immunochemical analysis. Of particular interest among the 20 newly diagnosed patients treated with the same therapeutic regimen, the median survival was 39 days for those with low RB protein expression compared to 333 days for those with high levels of RB protein expression in their leukemic cells (P 0.02). This preliminary study suggests that decreases of RB protein expression in peripheral blood of myeloid leukemic cells occur frequently and may be associated with shortened survival of acute myelogenous leukemia patients.

¹ This work was supported by the National Cancer Institute, Sid Richardson Foundation, the Gillson-Longenbaugh Foundation, the Kleberg Foundation, the Ladies Leukemia League of Louisiana, the Bush Leukemia Fund, the American Cancer Society (IM-580), and the Anderson Chair for Cancer Treatment and Research to A. B. D. This work was also supported by Grants R01 CA-54672 to W. F. B., Texas Advanced Technology Program Grant #4949019 to W. F. B. and H-J. X., and CA 16672 to T. L. S.

² To whom requests for reprints should be addressed, at the Department of Hematology, Box 24, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.

Received 3/30/92. Accepted 6/24/92.

This article has been cited by other articles:

				S. M. Kornblau, P. F. Thall, Z. Estrov, M. Walterscheid, S. Patel, A. Theriault, M. J. Keating, H. Kantarjian, E. Estey, and M. Andreeff The Prognostic Impact of BCL2 Protein Expression in Acute Myelogenous Leukemia Varies with Cytogenetics Clin. Cancer Res., July 1, 1999; 5(7): 1758 - 1766. [Abstract] [Full Text] [PDF]